A high-throughput neutralizing assay for antibodies and sera evaluation against Epstein-Barr virus

Abstract

Background Epstein-Barr virus (EBV) is a wide-spread human herpesvirus that is highly associated with infectious mononucleosis and several malignancies. Evaluation of EBV neutralizing antibody titers is important for serological studies, vaccine development and monoclonal antibody screening. The traditional method based on antibody inhibition of EBV transformation of B cells is very time-consuming. A more practical flow cytometry-based (FCM) approach to evaluate neutralizing titers is not amenable to achieving high-throughput evaluation of large-scale samples. A high-throughput approach is urgently needed. Results Here, we present a rapid and high-throughput method based on high content imaging system (HCIS) analysis. EBV titers determined by the HCIS-based assay were similar to those obtained by the FCM-based assay. Neutralizing titers of sera and monoclonal antibodies measured by the HCIS-based assay strongly correlated with titers measured by the FCM-based assay. HCIS assays showed a strong correlation between B cell infection neutralizing titers and the anti-gp350 IgG titers in healthy EBV carriers and monkey sera. Finally, anti-gHgL IgG titers from sera of healthy EBV carriers significantly correlated with epithelial cell infection neutralizing titers. Conclusions This HCIS-based assay is a high-throughput assay to determine viral titers and evaluate neutralizing potentials of sera and monoclonal antibodies. This HCIS-based assay will aid the development of vaccines and therapeutic monoclonal antibody against EBV.

Characterisation of the Antibody Response in Sinopharm (BBIBP-CorV) Recipients and COVID-19 Convalescent Sera from the Republic of Moldova

“…Following the HCI protocol, 15 samples can be simultaneously detected in a 96-well plate, while by FC cells from every well should be collected in an individual FC tube and independently analysed. High-throughput approaches are widely applied for drug discovery campaigns and have been recently implemented in neutralising assays [ 20 , 51 , 52 ]. We modified a 96-well HCI technique for SARS-CoV-2 [ 23 ].…”

A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection

“…CNE2-EBV cells and Akata-EBV cells carrying the Akata-EBV-GFP BAC were used to produce epithelial cells-derived EBV (CNE2-EBV-GFP) and B cells-derived EBV (Akata-EBV-GFP), respectively 84 . 20 ng/mL 12-O-tetradecanoylphorbol 13-acetate (TPA; Beyotime) and 2.5 mM sodium butyrate (NaB; Sigma Aldrich) were added to induce CNE2-EBV cells for 12 h and then medium was replaced by fresh complete medium.…”

Advancements of the Molecular Directed Design and Structure–Activity Relationship of Ferritin Nanocage

“…Additionally, the ferritin nanoparticle vaccines significantly activate the body's immune response to Epstein− Barr virus and hepatitis B virus. 226,227 Therefore, ferritin nanoparticle vaccines offer a promising and translatable vaccination strategy for disease prevention and cure. 6.7.…”